ENVB Stock Forecast: Enveric Biosciences, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 16 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Enveric Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (63): Sales and profits are climbing, and climbing faster than before.
Momentum (6): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ENVB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ENVB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 30 Jan 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 1 June 2022 | Alliance Global Partners | Initiates | Buy | $1.25 |
| 8 Mar 2022 | Aegis Capital | Downgrade | Hold | $7.00 → $0.20 |
| 8 July 2021 | Aegis Capital | Initiates | Buy | — |
| 28 June 2021 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
ENVB appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ENVB vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Enveric Biosciences, Inc. returned −76.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ENVB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.4×
- EV / EBITDA
- —
Cheaper than 90% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −170.0%
- Return on assets
- −87.3%
- Dividend yield
- —
Higher than 8% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Enveric Biosciences, Inc. has a market value of $6.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$8.7M.
Free cash flow in the twelve months to 30 June 2026: −$8.6M.
Enveric Biosciences, Inc. employs 5 people.
Data provided by Twelve Data
ENVB and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ENVB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Enveric Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ENVB
How does Ticker Nerd's model rank ENVB?
As at 21 Nov 2026, Enveric Biosciences, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (63 of 100).
What is the ENVB stock forecast for 2030?
No analyst covering Enveric Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENVB are extrapolating price history, which says nothing about the business.
How has ENVB stock performed over the past year?
Enveric Biosciences, Inc. returned -76.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Enveric Biosciences, Inc. do?
Enveric Biosciences Inc. is a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. The company’s current pipeline centers on novel compounds designed to promote neuroplasticity while avoiding hallucinogenic effects, with a particular emphasis on depression, anxiety, and addiction-related conditions.
About Enveric Biosciences, Inc.
Enveric Biosciences Inc. is a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. The company’s current pipeline centers on novel compounds designed to promote neuroplasticity while avoiding hallucinogenic effects, with a particular emphasis on depression, anxiety, and addiction-related conditions. Its lead program, EB-003, is being developed as a next-generation therapeutic candidate, and the broader research platform includes proprietary chemical libraries and additional preclinical assets aimed at mental health indications. Enveric Biosciences works at the intersection of neuroscience, medicinal chemistry, and drug discovery, positioning itself within the evolving field of psychedelic-inspired and neuropsychiatric medicine. The company is headquartered in Cambridge, Massachusetts.
CEO Dr. Joseph Edward Tucker Ph.D. · 5 employees · United States · https://www.enveric.com